================================================================================
BIOLOGY PLAN-EXECUTE DEMO
Multi-Domain Research Coordination with Codex GPT-5.2
Timestamp: 2026-02-19T01:31:29.876870
================================================================================

RESEARCH QUESTION:
The interplay between tumor-intrinsic genomic features and the tumor immune
microenvironment (TIME) has become central to precision immuno-oncology.

Please provide a comprehensive, multi-disciplinary analysis addressing ALL of
the following:

1. How do key tumor-intrinsic genomic features — including tumor mutational
   burden (TMB), microsatellite instability (MSI), specific driver mutations
   (e.g., KRAS, TP53, STK11/LKB1, KEAP1), and chromosomal instability (CIN)
   — vary across major cancer types, and what are the latest large-scale
   genomic studies characterizing these features?

2. At the molecular/protein level, how do these genomic alterations affect
   antigen presentation (MHC-I/II), immune checkpoint ligand expression
   (PD-L1, CTLA-4, LAG-3, TIGIT), and downstream signaling pathways
   (MAPK/ERK, PI3K/AKT/mTOR, JAK-STAT, cGAS-STING)? What are the
   structural and biochemical mechanisms involved?

3. How do these tumor-intrinsic features shape the composition and functional
   state of the tumor immune microenvironment — including CD8+ T cells,
   regulatory T cells, tumor-associated macrophages, myeloid-derived
   suppressor cells, and NK cells? What pathological patterns distinguish
   "hot" vs "cold" tumors?

4. Based on the above biology, what are the most promising biomarker-driven
   immunotherapy combination strategies currently in clinical trials
   (2023–2025), including checkpoint inhibitor combos, bispecifics,
   cancer vaccines, and cellular therapies? What recent clinical trial
   results have been most significant?


================================================================================
STEP 1: PLANNER — Decomposing into domain-specific sub-questions
================================================================================

Planner generated 4 sub-questions:

  1. Domain:  genomics-expert
     Question: Across major cancer types, how do TMB, MSI status, KRAS/TP53/STK11-KEAP1 driver alterations, and chromosomal instability (CIN) frequencies co-vary, and which 2018–2025 pan-cancer sequencing studies and updated compendia most comprehensively characterize these distributions?
     Terms:    pan-cancer TMB distribution, MSI prevalence across cancers, KRAS TP53 STK11 KEAP1 frequency by tumor type, chromosomal instability CIN pan-cancer, whole exome sequencing TCGA, PCAWG driver mutation landscape, cBioPortal pan-cancer, COSMIC Cancer Gene Census, MSK-IMPACT TMB, ICGC data portal

  2. Domain:  protein-biochemistry-expert
     Question: What molecular and structural mechanisms link TMB/MSI, KRAS/TP53/STK11-KEAP1 alterations, and CIN to changes in antigen presentation (MHC-I/II), immune checkpoint ligand expression (PD-L1, CTLA-4, LAG-3, TIGIT), and signaling pathways (MAPK/ERK, PI3K/AKT/mTOR, JAK-STAT, cGAS-STING), and which key protein-level studies elucidate these effects?
     Terms:    STK11 LKB1 antigen presentation MHC-I, KEAP1 NRF2 PD-L1 regulation, KRAS MAPK immune evasion, TP53 antigen presentation machinery, beta-2 microglobulin B2M loss MHC-I, cGAS-STING activation by CIN, JAK-STAT PD-L1 transcription, MHC-I peptide loading complex TAP1 TAP2, structural biology PD-L1 regulation, post-translational modification PD-L1

  3. Domain:  cancer-biology-expert
     Question: How do tumor-intrinsic features (TMB, MSI, KRAS/TP53/STK11-KEAP1, CIN) shape TIME composition and function—CD8+ T cells, Tregs, TAMs, MDSCs, NK cells—and what pathological features define ‘hot’ vs ‘cold’ tumors across cancer types?
     Terms:    STK11 LKB1 cold tumor microenvironment, KEAP1 NRF2 immune suppression, KRAS myeloid infiltration, TP53 immune microenvironment, MSI high CD8 infiltration, TMB neoantigen load immune infiltration, CIN cGAS-STING immune activation, pathology inflamed excluded desert tumor, TAM polarization M1 M2, MDSC expansion tumor

  4. Domain:  clinical-therapeutics-expert
     Question: Which biomarker-driven immunotherapy combination strategies (2023–2025) are most promising for tumors stratified by TMB/MSI, KRAS/TP53/STK11-KEAP1, and CIN, and what recent clinical trial results (checkpoint combos, bispecifics, vaccines, cellular therapies) show the most significant outcomes?
     Terms:    TMB high checkpoint inhibitor combination trial 2023 2024 2025, MSI-high immunotherapy combinations, STK11 KEAP1 NSCLC immunotherapy resistance trials, KRAS G12C + PD-1 combination trial, PD-1 LAG-3 TIGIT bispecific trial results, personalized neoantigen vaccine + checkpoint, CAR-T solid tumor trials 2023 2024, cGAS-STING agonist + immunotherapy, NCT trial identifiers, FDA approvals immunotherapy 2023 2025

================================================================================
STEP 2: DOMAIN EXPERTS — Parallel research execution
================================================================================

Launching 4 domain experts in parallel...


All 4 domain experts completed.

================================================================================
STEP 3: SYNTHESIZER — Integrating all findings into final report
================================================================================

Synthesizer is integrating all expert findings...

Synthesis completed in 97.3s


================================================================================
DOMAIN EXPERT REPORTS
================================================================================

──────────────────────────────────────────────────────────────────────
DOMAIN: cancer-biology-expert
──────────────────────────────────────────────────────────────────────
**Summary**  
Tumor‑intrinsic features shape TIME by tuning antigenicity (TMB/MSI), innate sensing (cGAS‑STING), and stromal/immune exclusion programs (TGF‑β, NRF2, LKB1). “Hot” tumors show intratumoral CD8 infiltration and IFN‑γ programs; “cold” tumors are either immune‑excluded (T cells trapped in stroma) or immune‑desert (absent immune cells). Across cancers, STK11/KEAP1 and high CIN/SCNA skew toward cold phenotypes, while MSI‑H and some TP53‑mutant contexts favor inflamed but often exhausted states. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5982584/?utm_source=openai))

**Pathological Immune Phenotypes (Hot vs Cold)**  
**Definitions and histopathology**  
Immune‑inflamed (hot) tumors have CD3+ cells within tumor nests; immune‑excluded tumors have CD3+ cells confined to stroma with little intratumoral penetration; immune‑desert tumors lack CD3+ cells in both stroma and tumor fields. ([elifesciences.org](https://elifesciences.org/articles/62927?utm_source=openai))  
Chen & Mellman’s framework formalized these phenotypes and their linkage to cancer–immune “set points.” ([nature.com](https://www.nature.com/articles/nature21349?utm_source=openai))

**Across cancer types: spatial prevalence**  
In resected PDAC, AI‑based spatial mapping showed 9.9% inflamed, 85.2% excluded, and 4.9% desert; median intratumoral TIL density was 100.64/mm² versus stromal 734.88/mm², illustrating dominant exclusion. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/40560550/?utm_source=openai))  
In resected NSCLC, ML‑based CD8 spatial phenotyping identified ~24.4% inflamed, 51.3% altered, and 24.3% desert tumors; STK11 and KEAP1 co‑mutations were enriched in non‑inflamed phenotypes. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/37100205/?utm_source=openai))

**Tumor‑Intrinsic Features Shaping TIME**

**TMB and neoantigen load**  
Higher mutation burden can associate with immune infiltration, but the relationship is tumor‑type dependent. A pan‑cancer analysis found mutation‑burden/infiltration correlations were strong only in colon adenocarcinoma; MSI+ vs MSI− colon differences were most pronounced for CD8 T cells, while B cells, NK cells, and macrophages showed smaller differences (P = 0.04, 8×10⁻⁴, and 0.09). ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5798883/?utm_source=openai))  
Copy‑number–driven (C‑class) tumors show weaker neoantigen‑dependent CTL infiltration than mutation‑driven (M‑class) tumors, indicating that TMB alone is insufficient to predict CD8 infiltration in high‑SCNA contexts. ([nature.com](https://www.nature.com/articles/s41467-018-03730-x?utm_source=openai))

**MSI‑H**  
A large CRC cohort (n = 1,236) showed MSI‑H tumors had significantly higher CD3+CD8+ T‑cell densities in epithelial regions; ORs for naive, memory, and regulatory CD8 subsets were 3.49, 2.82, and 3.04 versus MSS/MSI‑L. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39763680/?utm_source=openai))  
MSI‑H can still be functionally suppressed: in MSI‑H colon adenocarcinoma, high PD‑L1 tumors showed a 48.4% increase in Tregs and reduced GzmB and IFN‑γ positive cells, indicating an inflamed‑but‑exhausted state. ([nature.com](https://www.nature.com/articles/s41467-024-51386-7?utm_source=openai))  
Across cancers, MSI‑H’s immune impact varies by lineage, with weaker effects outside CRC, highlighting context dependence. ([academic.oup.com](https://academic.oup.com/bib/article/doi/10.1093/bib/bbaa180/5895437?utm_source=openai))

**KRAS**  
Oncogenic KRAS (G12D) drives GM‑CSF production that recruits Gr1+CD11b+ myeloid cells (MDSC‑like), establishing early immune suppression in pancreatic neoplasia. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/22698407/?utm_source=openai))  
In PDAC, tumor‑cell IL‑1β fosters desmoplasia and an immunosuppressive milieu rich in M2 macrophages and MDSCs; loss of tumor‑cell IL‑1β enables CD8 infiltration. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31915130/))  
Net effect: KRAS‑driven tumors often bias toward myeloid‑dominant, T‑cell‑excluded TIME, especially in desmoplastic cancers.

**TP53**  
Pan‑cancer TCGA immune profiling showed TP53 mutations correlate with higher leukocyte levels across tumors, implying that TP53 loss can shift TIME toward inflamed states in some lineages. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5982584/?utm_source=openai))  
However, co‑mutation context (e.g., KRAS + TP53 in PDAC) can still yield immunosuppressive, myeloid‑rich TIME, so TP53 effects are not uniform. ([sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S0753332223018565?utm_source=openai))

**STK11/LKB1**  
STK11‑deficient phenotypes show STING/Type I IFN disruption and CD8 dysfunction in NSCLC, decoupling CD8 presence from effective immunity. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/37495171/?utm_source=openai))  
In KL‑mutant models, STK11/LKB1 loss reduces TCF1+PD‑1+ stem‑like CD8 T cells; DC AXL suppresses Type I IFN, and AXL inhibition restores these CD8 subsets. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9040166/?utm_source=openai))  
Clinically relevant spatial phenotypes show STK11 and KEAP1 co‑mutations enriched in non‑inflamed/desert NSCLC. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/37100205/?utm_source=openai))

**KEAP1/NRF2**  
NRF2 activation (via KEAP1 loss) suppresses immune infiltration: KEAP1‑deleted tumors show reduced CD45+ infiltration (notably myeloid/monocytic), restored when NRF2 is also deleted. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12483591/?utm_source=openai))  
In KRAS/KEAP1 co‑mutant NSCLC, NRF2 inhibits the STING pathway, reinforcing immune suppression. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/37492744/?utm_source=openai))  
Mechanistically, this pushes TIME toward cold, T‑cell‑poor states with impaired innate sensing.

**CIN / Aneuploidy / SCNA**  
Across 5,255 TCGA tumors from 12 cancer types, high SCNA levels were linked to reduced cytotoxic immune signatures (especially CD8‑related) and increased proliferation markers; arm/chromosome SCNAs were the dominant predictors of immune suppression. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5592794/))  
CIN generates micronuclei that activate cGAS‑STING; in tumors, chronic activation drives noncanonical NF‑κB and metastasis, illustrating a protumor immune‑modulating effect. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29342134/?utm_source=openai))  
Reviews synthesize a dual role: acute STING signaling promotes DC activation and CD8/NK recruitment, while chronic CIN‑driven STING can induce PD‑L1 and immunosuppression. ([translational-medicine.biomedcentral.com](https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-025-06843-2?utm_source=openai))

**Single‑Cell and Spatial Transcriptomics Evidence**  
CRC scRNA‑seq + spatial transcriptomics mapped immune, stromal, and tumor regions and cell‑cell interactions, showing spatial proximity between stroma and tumor and distinct immune infiltration regions. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38729966/?utm_source=openai))  
PDAC spatial immune phenotyping quantified TIL densities and showed a predominance of immune‑excluded architecture at scale. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/40560550/?utm_source=openai))  
NSCLC spatial CD8 phenotyping linked STK11/KEAP1 co‑mutations to non‑inflamed/desert phenotypes. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/37100205/?utm_source=openai))  
These datasets reinforce that “hot vs cold” is fundamentally spatial, not just compositional.

**Key Resources Consulted**  
TCGA Pan‑Cancer immune landscape and immune subtypes (C1–C6). ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5982584/?utm_source=openai))  
Cancer Cell pan‑cancer TME subtypes (Bagaev et al., 2021). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/34019806/?utm_source=openai))  
CRI iAtlas portal for immune‑oncology datasets. ([cri-iatlas.org](https://cri-iatlas.org/?utm_source=openai))  
TIMER2.0 for immune‑infiltrate estimation and genomic associations. ([academic.oup.com](https://academic.oup.com/nar/article/48/W1/W509/5842187?utm_source=openai))  
CIBERSORTx digital cytometry for bulk‑to‑cell‑type deconvolution. ([nature.com](https://www.nature.com/articles/s41587-019-0114-2?utm_source=openai))

**Conflicting Evidence and Open Questions**  
MSI‑H is strongly immunogenic in CRC but shows weaker immune effects in other lineages; why mismatch repair defects translate differently across tissues remains unresolved. ([academic.oup.com](https://academic.oup.com/bib/article/doi/10.1093/bib/bbaa180/5895437?utm_source=openai))  
TMB does not uniformly predict immune infiltration; copy‑number–driven tumors can decouple neoantigen load from CTL entry, suggesting stromal or innate‑sensing barriers dominate. ([nature.com](https://www.nature.com/articles/s41467-018-03730-x?utm_source=openai))  
CIN/cGAS‑STING has bifunctional effects: acute activation supports immunity, while chronic activation can be immunosuppressive and metastatic. ([translational-medicine.biomedcentral.com](https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-025-06843-2?utm_source=openai))  
STK11 mutation is not always equivalent to STK11‑deficient phenotype; transcriptomic “deficiency” may be more relevant to TIME state than mutation status alone. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/37495171/?utm_source=openai))

**Most Significant Findings**  
MSI‑H consistently increases CD8 infiltration in CRC, but MSI‑H tumors can still be exhausted or Treg‑skewed. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39763680/?utm_source=openai))  
STK11/KEAP1 co‑alteration strongly biases toward cold, non‑inflamed phenotypes in NSCLC, aligning with suppressed STING/IFN signaling. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/37100205/?utm_source=openai))  
KRAS‑driven programs (GM‑CSF, IL‑1β) recruit MDSCs and M2 macrophages, promoting immune exclusion, especially in PDAC. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/22698407/?utm_source=openai))  
High CIN/SCNA correlates with reduced cytotoxic immune signatures and can rewire STING signaling toward immune evasion. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5592794/))

If you want, I can map these mechanisms to specific cancer types (NSCLC, CRC, PDAC, melanoma, breast) with a concise “feature → TIME phenotype” matrix and proposed biomarkers, still avoiding trial data.

──────────────────────────────────────────────────────────────────────
DOMAIN: clinical-therapeutics-expert
──────────────────────────────────────────────────────────────────────
Below is a focused, biomarker‑driven update (2023–2025) with trial names, NCTs, phases, endpoints, and quantitative outcomes. I prioritized peer‑reviewed publications and official regulatory/registry sources, and I flag where data are still conference‑reported or early.

**TMB/MSI‑High (Checkpoint Combinations, Tissue‑Agnostic and GI)**  
`TMB‑high, tumor‑agnostic`  
- **Nivolumab + ipilimumab vs nivolumab (NCT03668119, phase 2, randomized, TMB‑H solid tumors)**: ORR 38.6% with nivo+ipi vs 29.8% with nivo in tTMB‑H; ORR 22.5% vs 15.6% in bTMB‑H. Early/durable responses were seen in both tTMB‑H and bTMB‑H cohorts. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39107131/?utm_source=openai))  

`MSI‑H/dMMR mCRC`  
- **CheckMate 8HW (NCT04008030, phase 3)**:  
  - Nivo+ipi vs chemo (first‑line): median PFS not reached vs 5.8 months; HR 0.21; p<0.0001.  
  - Nivo+ipi vs nivo (all lines): median PFS not reached vs 39.3 months; HR 0.62; p=0.0003; ORR 71% vs 58%.  
  - Led to **FDA approval on April 8, 2025** for MSI‑H/dMMR unresectable or metastatic CRC (adult and pediatric ≥12); accelerated approval for single‑agent nivo converted to regular approval. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-ipilimumab-unresectable-or-metastatic-msi-h-or-dmmr-colorectal-cancer?utm_source=openai))  

**KRAS/TP53/STK11‑KEAP1 (NSCLC‑Focused)**  
`STK11/KEAP1‑mutant NSCLC (overcoming primary ICI resistance)`  
- **POSEIDON (NCT03164616, phase 3)**: tremelimumab + durvalumab + chemo (T+D+CT) vs chemo showed sustained OS benefit at 5‑year follow‑up (HR 0.76; 5‑year OS 15.7% vs 6.8%). The OS benefit remained evident in STK11‑mutant, KEAP1‑mutant, and KRAS‑mutant subsets. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39243945/?utm_source=openai))  
- **Biomarker‑stratified signal**: A 2024 Nature study integrating POSEIDON clinical data supports STK11/KEAP1 mutations as biomarkers for preferential benefit from adding CTLA‑4 blockade to PD‑(L)1 + chemo. ([nature.com](https://www.nature.com/articles/s41586-024-07943-7?utm_source=openai))  

`KRAS G12C + PD‑1 (emerging, conference‑reported)`  
- **KRYSTAL‑7 (NCT04613596, phase 2/3)**: In PD‑L1 TPS ≥50% cohort, conference‑reported data show ORR 63% (23/51; 95% CI 48–76), DCR 84%, median PFS not reached at data cut‑off, and median time‑to‑response 1.4 months. These results remain early and require phase 3 confirmation. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11153770/?utm_source=openai))  

`TP53`  
- As of 2023–2025, no prospective combination trial has published definitive **TP53‑stratified** outcomes with randomized endpoints. TP53 remains a hypothesis‑generating modifier rather than a validated selection biomarker in immunotherapy combinations.

**CIN (Chromosomal Instability)‑Linked Strategies**  
- No prospective immunotherapy combination trials have reported **CIN‑stratified** outcomes in 2023–2025. CIN is being explored indirectly via innate‑immune activation strategies, but patient selection by CIN remains investigational.  
- **STING agonist + PD‑1**: MIW815 (ADU‑S100) + spartalizumab (NCT03172936, phase Ib) showed ORR 10.4% with limited tumor responses overall; activity was modest and not CIN‑selected. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/36282874/?utm_source=openai))  

**Next‑Gen Checkpoints and Bispecifics**  
`PD‑1 × LAG‑3 bispecific`  
- **Tebotelimab (NCT03219268, phase 1, Nat Med 2023)**:  
  - Monotherapy expansion ORR 7% overall; ORR 11% in EOC, 6% in TNBC, 14% in CPI‑naïve NSCLC; median DoR 12.1 months in responders.  
  - In HER2+ tumors with tebotelimab + margetuximab, ORR 19% (14/72) and median DoR 16.7 months.  
  ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10667103/))  

`TIGIT`  
- **SKYSCRAPER‑01 (NCT04294810, phase 3)**: tiragolumab + atezolizumab did **not** meet the OS endpoint in PD‑L1‑high, previously untreated NSCLC at final analysis; Roche reported no new safety signals and data presentation pending. ([roche.com](https://www.roche.com/media/releases/med-cor-2024-11-26?utm_source=openai))  

**Vaccines (Neoantigen‑Directed + Checkpoint)**  
- **KEYNOTE‑942 (NCT03897881, phase 2b; Weber et al., Lancet 2024)**: mRNA‑4157/V940 + pembrolizumab vs pembrolizumab in resected high‑risk melanoma showed improved RFS (HR 0.561; p=0.053), with 18‑month RFS 79% vs 62%. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38246194/))  

**Cellular Therapies (Solid Tumors)**  
- **Lifileucel (Amtagvi) TIL therapy**: FDA accelerated approval **Feb 16, 2024** for unresectable/metastatic melanoma after PD‑1 and (if BRAF V600+) targeted therapy. In C‑144‑01 (NCT02360579), ORR 31.5% with 4.1% CR; median DoR not reached; durable responses maintained in 56.5% at 6 months, 47.8% at 9 months, 43.5% at 12 months. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/40699950/?utm_source=openai))  

**FDA Approvals / Breakthrough Designations (2023–2025)**  
- **April 8, 2025**: FDA approval of nivolumab + ipilimumab for MSI‑H/dMMR unresectable/metastatic CRC; priority review and breakthrough designation noted in FDA summary. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-ipilimumab-unresectable-or-metastatic-msi-h-or-dmmr-colorectal-cancer?utm_source=openai))  
- **Feb 16, 2024**: FDA accelerated approval of lifileucel (Amtagvi) for advanced melanoma after PD‑1 (and BRAF/MEK if applicable). ([fda.gov](https://www.fda.gov/news-events/press-announcements/fda-approves-first-cellular-therapy-treat-patients-unresectable-or-metastatic-melanoma?utm_source=openai))  

**Conflicting Evidence / Open Questions**  
- TIGIT remains uncertain after **SKYSCRAPER‑01** failed OS despite strong phase 2 signals. ([roche.com](https://www.roche.com/media/releases/med-cor-2024-11-26?utm_source=openai))  
- STING agonist combinations (e.g., MIW815 + PD‑1) show limited ORR and have not been validated in CIN‑selected cohorts. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/36282874/?utm_source=openai))  
- KRAS G12C + PD‑1 combinations show encouraging response rates in PD‑L1‑high cohorts, but randomized phase 3 confirmation and toxicity characterization are still pending. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11153770/?utm_source=openai))  

**Most Significant Findings (2023–2025)**  
1. **MSI‑H/dMMR mCRC**: CheckMate 8HW establishes dual ICI as a high‑impact standard, with dramatic PFS benefit and FDA approval in April 2025. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-ipilimumab-unresectable-or-metastatic-msi-h-or-dmmr-colorectal-cancer?utm_source=openai))  
2. **STK11/KEAP1‑mutant NSCLC**: POSEIDON long‑term OS and the Nature biomarker analysis support adding CTLA‑4 blockade to PD‑(L)1 + chemo for this resistance phenotype. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39243945/?utm_source=openai))  
3. **Personalized neoantigen vaccine**: mRNA‑4157/V940 + pembrolizumab shows meaningful RFS improvement in high‑risk melanoma (KEYNOTE‑942). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38246194/))  
4. **TMB‑H tissue‑agnostic**: randomized phase 2 data show higher ORR with nivo+ipi vs nivo in TMB‑H tumors. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39107131/?utm_source=openai))  
5. **TIL therapy**: lifileucel’s FDA approval marks the first solid‑tumor cellular therapy with durable responses in heavily pretreated melanoma. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/40699950/?utm_source=openai))  

**Resources Consulted**  
- ClinicalTrials.gov (trial design, NCTs). ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03164616?utm_source=openai))  
- FDA approvals and official drug summaries. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-ipilimumab-unresectable-or-metastatic-msi-h-or-dmmr-colorectal-cancer?utm_source=openai))  
- Peer‑reviewed journals: Lancet, Nature, Nat Med, J Thorac Oncol, Clin Cancer Res. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38246194/))  

If you want, I can expand with tumor‑type‑specific tables (CRC, NSCLC, melanoma, others) or map each biomarker to “ready‑for‑practice” vs “investigational” combinations.

──────────────────────────────────────────────────────────────────────
DOMAIN: protein-biochemistry-expert
──────────────────────────────────────────────────────────────────────
**Scope**  
Focused on protein-level mechanisms and structural studies that connect TMB/MSI, KRAS/TP53/STK11‑KEAP1, and CIN to antigen presentation, checkpoint regulation, and key signaling axes. No clinical trial or epidemiology content.

**Key Structural Anchors (PDB IDs)**  
- PD‑1/PD‑L1 IgV interface: `4ZQK` (human PD‑1–PD‑L1 complex). ([rcsb.org](https://www.rcsb.org/structure/4ZQK?utm_source=openai))  
- PD‑L1 dimerization that occludes the PD‑1 surface: `5J89` (PD‑L1 + BMS‑202). ([rcsb.org](https://www.rcsb.org/structure/5J89?utm_source=openai))  
- MHC‑I heavy chain with β2‑microglobulin and peptide: `1AKJ` (HLA‑A2–β2m–peptide complex). ([rcsb.org](https://www.rcsb.org/structure/1AKJ?utm_source=openai))  
- TAP1/TAP2 transporter: `5U1D` (human TAP1/2 cryo‑EM). ([rcsb.org](https://www.rcsb.org/structure/5U1D?utm_source=openai))  
- Peptide‑loading complex (PLC): `6ENY` (human PLC with TAP, tapasin, calreticulin, ERp57, MHC‑I). ([nature.com](https://www.nature.com/articles/nature24627))  
- Tapasin–MHC‑I editing complex: `7TUE` (tapasin–HLA‑B*44:05–β2m). ([nature.com](https://www.nature.com/articles/s41467-022-33153-8))  
- cGAS–DNA and STING–cGAMP: `6CT9` (cGAS–DNA) and `4KSY` (STING–2’3’‑cGAMP). ([www3.rcsb.org](https://www3.rcsb.org/structure/6CT9?utm_source=openai))  
- LAG‑3–HLA‑DR1 complex: `9BF9` (human LAG‑3–HLA‑DR1). ([rcsb.org](https://www.rcsb.org/structure/9bf9?utm_source=openai))  
- TIGIT–CD155 complex: `3UDW` (TIGIT bound to CD155 D1). ([rcsb.org](https://www.rcsb.org/structure/3UDW?utm_source=openai))  
- CTLA‑4–CD80 complex: `1I8L` (B7‑1/CTLA‑4). ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/Structure/pdb/1I8L?utm_source=openai))  

**Mechanistic Links**  

**TMB/MSI → Antigen Presentation Defects**  
- MSI colorectal cancers show heavy selection for antigen‑presentation pathway (APM) lesions: 72% (66/91) had mutations in at least one APM component (B2M, HLA‑A/B/C, TAP1/2, NLRC5), and B2M was mutated in 30.8% with 96.4% truncating. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5993484/?utm_source=openai))  
- A separate MSI‑H/dMMR cohort reported B2M mutation rates of 57.5% in CRC (23/40), 23.9% in gastric cancer (11/46), and 13.6% in endometrial cancer (3/22), with 11% biallelic disruption in MSI‑H CRC. ([academic.oup.com](https://academic.oup.com/oncolo/article/28/3/e136/7022155?utm_source=openai))  
- B2M is the obligate light chain for MHC‑I stability and peptide display, structurally evident in HLA‑A2–β2m complexes (`1AKJ`), and annotated as the β2‑microglobulin protein in UniProt (P61769). ([rcsb.org](https://www.rcsb.org/structure/1AKJ?utm_source=openai))  
- The PLC architecture (`6ENY`) and tapasin‑MHC‑I editing structures (`7TUE`) provide a mechanistic framework for how TAP/tapasin disruption reduces peptide loading and surface MHC‑I. ([nature.com](https://www.nature.com/articles/nature24627))  

**CIN → cGAS–STING → JAK‑STAT → PD‑L1/MHC (Inference‑Based Link)**  
- Chromosomal instability generates micronuclei; micronuclear envelope rupture allows cGAS access to genomic DNA, triggering STING signaling and innate immune activation. ([nature.com](https://www.nature.com/articles/nature23449?utm_source=openai))  
- The structural basis of DNA sensing and STING activation is captured in cGAS–DNA (`6CT9`) and STING–cGAMP (`4KSY`) complexes. ([www3.rcsb.org](https://www3.rcsb.org/structure/6CT9?utm_source=openai))  
- IFN‑driven JAK1/2‑STAT1/IRF1 signaling directly controls PD‑L1 and antigen‑presentation gene induction; IRF1 binds the PD‑L1 promoter after IFN‑γ stimulation. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6420824/?utm_source=openai))  
- Inference: CIN‑driven cGAS‑STING activation can feed into IFN‑JAK‑STAT pathways that elevate MHC and PD‑L1, while chronic activation may shift toward immune suppression (see open questions). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38273467/?utm_source=openai))  

**KRAS G12C/D/V → MAPK/ERK → PD‑L1**  
- Codon 12 KRAS mutations impair GAP‑mediated GTP hydrolysis and stabilize the active, GTP‑bound state; G12D is explicitly enriched in the GTP‑bound signaling state. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31611389/?utm_source=openai))  
- In KRAS‑mutant lung adenocarcinoma cells, MEK inhibition (U0126) reduced PD‑L1 surface levels by ~50–60% (p < 0.0001), and an AP‑1 site in the PD‑L1 gene was functionally bound by cJUN, establishing MAPK/ERK→AP‑1 control of PD‑L1. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5112979/))  
- STAT3 contributed partially to PD‑L1 regulation in the same models, while PI3K inhibition (LY294002) had no effect in that context, placing MAPK/ERK as the dominant driver. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5112979/))  

**TP53 Hotspots → Antigen Presentation Machinery**  
- TP53 hotspot missense mutations cluster in the DNA‑binding domain (e.g., R175H, R248Q/W, R273H) and are enriched in tumor datasets, consistent with loss of DNA‑binding/transactivation functions. ([insight.jci.org](https://insight.jci.org/articles/view/128439?utm_source=openai))  
- Wild‑type p53 directly induces TAP1, enhancing peptide transport into the ER and increasing surface MHC‑I–peptide complexes. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/10618714/?utm_source=openai))  
- p53 also upregulates ERAP1, increasing peptide trimming and MHC‑I expression. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3759077/?utm_source=openai))  
- Loss‑of‑function TP53 (including hotspot missense) therefore suppresses TAP1/ERAP1‑dependent antigen presentation, shifting the tumor surface toward reduced MHC‑I. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/10618714/?utm_source=openai))  
- p53 loss can blunt IFN‑γ‑induced PD‑L1 via reduced JAK2 signaling, linking TP53 status to JAK‑STAT checkpoint induction. ([jeccr.biomedcentral.com](https://jeccr.biomedcentral.com/articles/10.1186/s13046-019-1403-9?utm_source=openai))  

**STK11/LKB1 Loss → STING Silencing and Immune Cold State**  
- LKB1 loss in KRAS‑driven lung cancers causes transcriptional silencing of STING via DNMT1/EZH2‑linked epigenetic mechanisms, rendering cells insensitive to cytosolic dsDNA and dampening IFN signaling. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/30297358/?utm_source=openai))  
- This provides a direct molecular bridge from STK11 loss to cGAS‑STING shutdown and reduced interferon‑driven PD‑L1/chemokine programs. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6328329/?utm_source=openai))  

**KEAP1/NRF2 Axis → PD‑L1 and Innate Sensing**  
- A recent CRISPR screen showed KEAP1 depletion or pharmacologic inhibition reduces PD‑L1 transcription; NRF2 activation is the driver, with ChIP‑qPCR demonstrating NRF2 binding at a PD‑L1 enhancer. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12630863/?utm_source=openai))  
- KEAP1 or STK11 mutant lung tumors display a redox phenotype with suppressed STING/MDA5 expression and interferon signaling, aligning KEAP1/NRF2 biology with innate immune silencing. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12685646/?utm_source=openai))  

**PD‑L1 Protein‑Level Control (PTMs)**  
- PD‑L1 stability is regulated by GSK3β‑dependent phosphorylation that recruits β‑TrCP for ubiquitination and proteasomal degradation; N‑glycosylation at N192/N200/N219 blocks GSK3β binding and stabilizes PD‑L1. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/27572267/?utm_source=openai))  

**Checkpoint Receptor/Ligand Structural Context**  
- CTLA‑4–CD80 (`1I8L`), TIGIT–CD155 (`3UDW`), and LAG‑3–HLA‑DR1 (`9BF9`) structures define the physical interfaces governing checkpoint inhibition and ligand availability on APCs or tumor cells. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/Structure/pdb/1I8L?utm_source=openai))  
- These interfaces explain how altered ligand abundance (CD80/CD155/HLA‑DR) can change inhibitory signaling, even when PD‑L1 is not the dominant checkpoint ligand. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/Structure/pdb/1I8L?utm_source=openai))  

**Conflicting Evidence / Open Questions**  
- NRF2 shows context‑dependent effects on PD‑L1: KEAP1 loss/NRF2 activation suppresses PD‑L1 in a recent CRISPR screen, yet colon cancer data report NRF2 and PD‑L1 mRNA co‑elevation and PD‑L1 reduction upon NRF2 inhibition. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12630863/?utm_source=openai))  
- cGAS‑STING activation can drive antitumor immunity, but sustained signaling may remodel an immunosuppressive environment; the balance likely depends on CIN burden, STING competence, and chronic stress. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38273467/?utm_source=openai))  
- MSI tumors show diverse APM lesions (B2M vs NLRC5 vs HLA/TAP), suggesting partial versus complete MHC‑I loss varies by lesion and may differentially shape MHC‑II and checkpoint profiles. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5993484/?utm_source=openai))  

**Resources Consulted**  
- RCSB PDB for structural models (`4ZQK`, `5J89`, `6ENY`, `7TUE`, `5U1D`, `6CT9`, `4KSY`, `9BF9`, `3UDW`, `1I8L`). ([rcsb.org](https://www.rcsb.org/structure/4ZQK?utm_source=openai))  
- PubMed/PMC primary literature (MSI APM defects, KRAS–MAPK–PD‑L1, LKB1–STING, PD‑L1 PTMs, IFN‑JAK‑STAT). ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5993484/?utm_source=openai))  
- UniProt REST entry for β2‑microglobulin (P61769). ([rest.uniprot.org](https://rest.uniprot.org/uniprotkb/P61769.txt))  

**Summary**  
TMB/MSI and CIN primarily rewire immunity through antigen‑presentation capacity and DNA‑sensing pathways: MSI tumors frequently acquire disabling mutations in B2M/HLA/TAP/NLRC5, while CIN generates micronuclear DNA that can activate cGAS‑STING and IFN‑JAK‑STAT programs that induce PD‑L1 and antigen‑presentation genes. KRAS G12C/D/V mutations lock KRAS in an active state that drives MAPK/ERK‑AP‑1–dependent PD‑L1 transcription, whereas TP53 loss removes transcriptional control of TAP1 and ERAP1. STK11/LKB1 loss and KEAP1/NRF2 alterations converge on silencing STING and interferon responses, with NRF2 showing context‑dependent effects on PD‑L1 transcription. Structural studies of PD‑1/PD‑L1, PLC/tapasin, cGAS‑STING, and LAG‑3/TIGIT/CTLA‑4 complexes provide protein‑level anchors for these mechanistic links.

──────────────────────────────────────────────────────────────────────
DOMAIN: genomics-expert
──────────────────────────────────────────────────────────────────────
Using the `web-search` skill to pull the latest (2018–2025) sources and quantify key distributions.

**Pan‑Cancer Sequencing Studies & Compendia (2018–2025)**  
Most comprehensive, broadly used resources that directly support cross‑tumor comparisons of TMB/MSI/CIN and driver alterations:

- **TCGA Pan‑Cancer Atlas (2018, Cell)**: 9,423 exomes across 33 cancers; 299 driver genes identified; foundational for pan‑cancer driver/alteration baselines. ([gdc.cancer.gov](https://gdc.cancer.gov/publications/pancan-driver?utm_source=openai))  
- **PCAWG (ICGC/TCGA, Nature 2020)**: >2,500 whole genomes; 91% of tumors have at least one driver; includes SV/CNA and WGS‑based drivers. ([nature.com](https://www.nature.com/articles/s41586-020-1969-6?utm_source=openai))  
- **Pan‑Cancer Atlas mutation burden analysis (JCO Precision Oncology 2023)**: pan‑cancer distributions of SNV/TMB and CNA fraction, showing these as distinct axes of genomic burden. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/37276492/?utm_source=openai))  
- **cBioPortal 2024 update**: integrates TCGA + GENIE with enhanced joint clinical–genomic analysis capabilities (critical for cross‑study comparisons). ([cancer.gov](https://www.cancer.gov/about-nci/organization/cbiit/news-events/news/2024/cbioportal-updates-offer-joint-analysis-genetic-and-clinical-data?utm_source=openai))  
- **AACR GENIE 2025 release**: >268,000 samples, ~250,000 patients; large real‑world genomic resource for mutation frequencies and TMB. ([aacr.org](https://www.aacr.org/professionals/research/aacr-project-genie/news-updates/year-in-review-2025/?utm_source=openai))  
- **IntOGen 2024 release (driver compendium; integrates COSMIC CGC v99)**: ~33k samples, 87 cancer types, 633 drivers; current driver catalog overlay. ([intogen.org](https://www.intogen.org/releasednotes?utm_source=openai))  

**Pan‑Cancer Distributions: TMB, MSI, CIN (Quantitative)**

**TMB**  
- **Pan‑cancer prevalence of TMB‑high** in adults (meta‑analysis):  
  - ≥10 mut/Mb: **14.0%**  
  - ≥17 mut/Mb: **8.4%**  
  - ≥20 mut/Mb: **6.6%** ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9705554/?utm_source=openai))  
- **Pan‑cancer TMB boundaries** (TCGA Pan‑Cancer Atlas survival analysis): TMB sextile cut‑points at **0.688, 1.22, 2.00, 3.27, 7.10 mut/Mb**. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/37276492/?utm_source=openai))  
- **Cancer‑specific TMB cutoffs vary widely** (MSK‑IMPACT cohort): top‑20% TMB cutoffs reported as **CRC 52.2**, **bladder 17.6**, **breast 5.9 mut/Mb** (illustrating large histology‑specific shifts). ([sciencedirect.com](https://www.sciencedirect.com/topics/medicine-and-dentistry/tumor-mutation-burden?utm_source=openai))  
- **Example (breast, 2025 MSK‑IMPACT)**: mean **4.6 mut/Mb**, median **3.5**, and **6.7%** TMB‑high (≥10). ([nature.com](https://www.nature.com/articles/s41698-025-01045-x?utm_source=openai))  

**MSI**  
- **Large pan‑cancer tissue cohort (2024, F1CDx; 174,166 advanced cancers)**: overall **2.4% MSI‑H**; high rates in endometrioid endometrial carcinoma **32%**, small‑intestine adenocarcinoma **10%**, CRC **7%**, gastric adenocarcinoma **6%**, multiple other tumor types <5%. ([nature.com](https://www.nature.com/articles/s41698-024-00679-7?utm_source=openai))  
- **Literature synthesis across 39 tumor types**: MSI seen in **3.8% overall**; typical prevalence **CRC 10.2%**, **endometrial 21.9%**, **gastric 8.5%**. ([mdpi.com](https://www.mdpi.com/2072-6694/15/8/2288?utm_source=openai))  
- **ctDNA‑based MSI (2023, 171,881 patients)**: **1.4%** MSI‑H overall, highlighting assay/platform differences. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/37769226/?utm_source=openai))  

**CIN / Aneuploidy / CNA burden**  
- **TCGA aneuploidy study (2018, Cancer Cell)**: 10,522 genomes; aneuploidy correlates with **TP53 mutation** and somatic mutation rate, indicating CIN as a distinct (and TP53‑linked) axis of genomic instability. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29622463/?utm_source=openai))  
- **Pan‑Cancer Atlas (2023)** explicitly models **CNA fraction** separately from SNV/TMB, supporting CIN as an orthogonal burden class rather than a proxy for TMB. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/37276492/?utm_source=openai))  

**Driver Alteration Frequencies (Major Cancer Types)**  
(Representative pan‑cohort or TCGA‑anchored frequencies; focus on KRAS/TP53/STK11/KEAP1)

| Cancer type (dataset) | KRAS | TP53 | STK11 | KEAP1 | Notes |
|---|---:|---:|---:|---:|---|
| **LUAD (4,109 cases; 2024 LUAD meta‑cohort)** | **34.17%** | **45.6%** | **16.82%** | **14.35%** | LUAD shows strong KRAS/STK11/KEAP1 co‑mutation clustering. ([frontiersin.org](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1357583/full?utm_source=openai)) |
| **CRC (TCGA cohort)** | **40.49%** | **59.70%** | — | — | APC 76.65% (context: classic CIN/MSS subset). ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8034139/?utm_source=openai)) |
| **PDAC (TCGA vs GENIE/MSK)** | **65.4% (TCGA)** | **~60% (TCGA)** | — | — | KRAS approaches **~90%** and TP53 **~70%** in larger MSK‑IMPACT/GENIE cohorts. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8382872/?utm_source=openai)) |
| **HGSOC (TCGA)** | rare | **96%** | — | — | archetypal CIN‑high tumor with ubiquitous TP53 and extensive CNAs. ([journals.lww.com](https://journals.lww.com/intjgynpathology/fulltext/2022/11001/data_set_for_the_reporting_of_ovarian%2C_fallopian.9.aspx?utm_source=openai)) |
| **Adenocarcinoma vs SCC (pan‑carcinoma)** | **14% vs 1%** | **34% vs 63%** | — | — | Highlights TP53‑CIN alignment in SCC and KRAS enrichment in adenocarcinoma. ([nature.com](https://www.nature.com/articles/s41467-021-26213-y?utm_source=openai)) |

**Co‑variation Patterns (TMB, MSI, CIN, Drivers)**

**1) MSI‑high → high TMB, often lower CIN**  
- MSI‑H is concentrated in **endometrial, CRC, gastric, small‑intestine** tumors (MSI‑H 6–32% depending on site and cohort), which are also enriched for TMB‑high cases. ([nature.com](https://www.nature.com/articles/s41698-024-00679-7?utm_source=openai))  
- Inference: MSI‑high subsets inflate TMB in these tumor types, while CIN‑high subsets (e.g., MSS CRC) carry more CNAs. This split underlies the classic MSI vs CIN dichotomy in CRC and STAD. (Inference grounded in MSI prevalence + CIN‑TP53 linkage.) ([nature.com](https://www.nature.com/articles/s41698-024-00679-7?utm_source=openai))  

**2) Smoking‑related NSCLC: high TMB, low MSI; KRAS‑STK11‑KEAP1 cluster in LUAD**  
- LUAD shows **KRAS 34%, STK11 16.8%, KEAP1 14.4%**, TP53 45.6% with documented co‑mutation patterns. ([frontiersin.org](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1357583/full?utm_source=openai))  
- MSI‑H is rare in lung cancer in pan‑cancer prevalence studies (<5% overall “other malignancies”). ([nature.com](https://www.nature.com/articles/s41698-024-00679-7?utm_source=openai))  
- Inference: NSCLC’s high TMB is driven primarily by mutational processes rather than MSI, with co‑mutational KRAS/STK11/KEAP1 shaping a low‑MSI, moderate‑to‑high CIN landscape. (Inference grounded in LUAD co‑mutation frequencies + MSI prevalence.) ([frontiersin.org](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1357583/full?utm_source=openai))  

**3) CIN‑dominant tumors align with very high TP53**  
- HGSOC shows **TP53 96%** with pervasive CNAs. ([journals.lww.com](https://journals.lww.com/intjgynpathology/fulltext/2022/11001/data_set_for_the_reporting_of_ovarian%2C_fallopian.9.aspx?utm_source=openai))  
- Aneuploidy correlates with TP53 at pan‑cancer scale. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29622463/?utm_source=openai))  
- Inference: TP53‑high tumor types (HGSOC, many SCCs) are enriched for CIN‑high phenotypes even when TMB/MSI are low. (Inference grounded in TP53 frequency + aneuploidy correlation.) ([journals.lww.com](https://journals.lww.com/intjgynpathology/fulltext/2022/11001/data_set_for_the_reporting_of_ovarian%2C_fallopian.9.aspx?utm_source=openai))  

**4) CRC: dual genomic regimes**  
- **KRAS 40.49%**, **TP53 59.70%** overall TCGA CRC indicates dominant CIN/MSS majority. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8034139/?utm_source=openai))  
- MSI‑H occurs in **~7–10%** (advanced vs mixed‑stage cohorts), producing a high‑TMB subset. ([nature.com](https://www.nature.com/articles/s41698-024-00679-7?utm_source=openai))  

**Conflicting Evidence / Open Questions**

- **MSI prevalence varies by assay**: tissue‑based MSI‑H at **2.4–3.8%** overall vs **1.4%** in ctDNA, indicating platform‑dependent sensitivity and cohort composition effects. ([nature.com](https://www.nature.com/articles/s41698-024-00679-7?utm_source=openai))  
- **TMB “high” is not a universal threshold**: top‑20% cutoffs differ drastically by histology (e.g., CRC 52.2 vs breast 5.9 mut/Mb), complicating pan‑cancer comparisons. ([sciencedirect.com](https://www.sciencedirect.com/topics/medicine-and-dentistry/tumor-mutation-burden?utm_source=openai))  
- **CIN quantification is not standardized**: aneuploidy scores, CNA fraction, and SCNA burden are related but not identical; pan‑cancer studies treat CNA burden as an independent axis. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29622463/?utm_source=openai))  
- **Driver frequency variation by cohort**: TCGA vs GENIE/MSK often diverge (e.g., KRAS in PDAC 65% TCGA vs ~90% in GENIE/MSK), reflecting clinical‑grade cohort enrichment. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8382872/?utm_source=openai))  

**Summary (Most Significant Findings)**  
- **TMB‑high is relatively uncommon pan‑cancer (≈14% at ≥10 mut/Mb)** and highly tumor‑type dependent. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9705554/?utm_source=openai))  
- **MSI‑H is rare overall (≈2–4%) but highly enriched in endometrial, CRC, gastric, small‑intestine cancers**, producing a distinct high‑TMB subset. ([nature.com](https://www.nature.com/articles/s41698-024-00679-7?utm_source=openai))  
- **CIN/aneuploidy tracks with TP53 alterations** and defines a second major instability axis separate from TMB. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29622463/?utm_source=openai))  
- **Driver landscapes** show strong tumor‑type specificity: LUAD is enriched for **KRAS/STK11/KEAP1**, CRC for **KRAS/TP53/APC**, PDAC for **KRAS/TP53**, and HGSOC for **near‑ubiquitous TP53**, aligning with CIN‑high biology. ([frontiersin.org](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1357583/full?utm_source=openai))  

If you want, I can add a matrix that explicitly maps each cancer type to **(TMB tier / MSI prevalence / CIN tier / driver frequency)** using a consistent numeric cut‑off scheme (e.g., TMB ≥10 mut/Mb; MSI‑H %; TP53 as CIN proxy), but that would require agreeing on standardized thresholds.

━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
INTEGRATED SYNTHESIS REPORT
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

**I. Executive Summary**  
- Pan‑cancer, tumor‑intrinsic genomic axes separate into mutation‑driven (TMB/MSI) vs copy‑number–driven (CIN/SCNA) instability, with MSI‑H rare overall (≈2–4%) but enriched in endometrial/CRC/gastric, while CIN aligns strongly with TP53 alterations. [R1–R8, R11–R15]  
- MSI‑H tumors are immunogenic yet frequently acquire antigen‑presentation machinery (APM) lesions (e.g., B2M/HLA/TAP/NLRC5), explaining inflamed‑but‑exhausted states and immune escape despite high TMB. [R16–R19, R37]  
- KRAS, STK11/LKB1, and KEAP1/NRF2 rewire innate sensing and PD‑L1 regulation via MAPK/ERK‑AP‑1 and cGAS‑STING–IFN pathways, biasing many tumors toward myeloid‑dominant, T‑cell‑excluded “cold” phenotypes. [R20–R31, R43–R47]  
- Spatial pathology defines TIME: “hot” tumors show intratumoral CD3+/CD8+ cells; “excluded” tumors have stromal‑trapped T cells; “desert” tumors lack immune cells. PDAC is predominantly excluded (≈85%), and NSCLC shows substantial non‑inflamed fractions enriched for STK11/KEAP1 co‑mutations. [R32–R36, R41–R42]  
- The most practice‑changing clinical data (2023–2025) are MSI‑H/dMMR CRC dual‑checkpoint efficacy (CheckMate 8HW) with FDA approval on **April 8, 2025**, and durable benefit signals in STK11/KEAP1‑mutant NSCLC when CTLA‑4 is added to PD‑(L)1 + chemotherapy. [R48–R52]  
- Emerging modalities (neoantigen vaccines, TIL therapy, bispecifics) show promise but remain disease‑restricted or early‑phase, while TIGIT has a major late‑phase failure and STING agonists show limited activity to date. [R53–R58]

---

**II. Integrated Analysis (Genome → Protein → TIME → Clinical Outcomes)**  
**1) Genomic landscape and cross‑tumor variability**  
Large sequencing compendia (TCGA Pan‑Cancer, PCAWG, GENIE, IntOGen) establish two dominant instability axes: mutation‑driven (TMB/MSI) and copy‑number–driven (CIN/aneuploidy/CNA fraction). [R1–R5, R11–R12]  
- **TMB**: Pan‑cancer TMB‑high prevalence is ~14% at ≥10 mut/Mb, but cutoffs vary sharply by histology (e.g., CRC top‑20% around ~52 mut/Mb vs breast ~5.9 mut/Mb). [R6–R7]  
- **MSI‑H**: Overall 2–4% (tissue cohorts) with high enrichment in endometrial (~32%), CRC (~7–10%), gastric (~6–9%), and small‑intestine (~10%); ctDNA‑based MSI‑H is lower (~1.4%), reflecting assay sensitivity and cohort bias. [R8–R10]  
- **CIN**: Aneuploidy and CNA fraction are distinct from TMB and correlate with TP53 alterations; CIN‑high archetypes include HGSOC (TP53 ~96%) and many squamous carcinomas. [R11–R15]  
- **Driver distributions**: LUAD shows KRAS 34%, STK11 16.8%, KEAP1 14.4%, TP53 45.6% with co‑mutation clustering; CRC is KRAS 40.5%, TP53 59.7% (CIN/MSS‑dominant); PDAC approaches KRAS ~90% and TP53 ~70% in clinical cohorts; these driver contexts set the baseline immune program. [R12–R14]

**2) Protein‑level mechanisms linking genomics to immune signaling**  
**Antigen presentation (APM/MHC‑I):**  
- MSI‑H CRCs are enriched for APM lesions: ~72% have ≥1 APM mutation; B2M is mutated in ~30.8% (mostly truncating), with similar patterns across MSI‑H tumors in other tissues. [R16–R18]  
- B2M is structurally essential for MHC‑I stability (HLA‑A2–β2m complex), while the peptide‑loading complex and tapasin editing structures explain how TAP/tapasin defects reduce surface MHC‑I. [R19–R21]  
**Innate sensing and IFN signaling:**  
- CIN generates micronuclei; cGAS senses DNA, activating STING and IFN programs. These structural bases are captured in cGAS–DNA and STING–cGAMP complexes. [R22–R23]  
- IFN‑γ–JAK‑STAT–IRF1 drives PD‑L1 and APM gene induction, linking innate sensing to checkpoint expression. [R24]  
**Oncogenic signaling → checkpoint control:**  
- KRAS codon‑12 mutants stabilize GTP‑bound KRAS, activating MAPK/ERK; PD‑L1 transcription is driven via AP‑1, and MEK inhibition reduces PD‑L1 in KRAS‑mutant lung models. [R25–R26]  
- TP53 normally upregulates TAP1 and ERAP1, promoting peptide loading; TP53 loss suppresses APM and can dampen JAK2‑mediated PD‑L1 induction. [R27–R29]  
- STK11/LKB1 loss epigenetically silences STING (DNMT1/EZH2‑linked), reducing IFN signaling and immune recruitment. [R30–R31]  
- KEAP1/NRF2 alterations suppress STING/MDA5 and can reduce PD‑L1 transcription in some contexts; in others, NRF2 correlates with higher PD‑L1, underscoring context dependence. [R31–R33]  
**Checkpoint structure/function anchors:**  
- PD‑1/PD‑L1, CTLA‑4/CD80, TIGIT/CD155, LAG‑3/HLA‑DR structures define inhibitory interfaces and explain how altered ligand availability modulates signaling independent of PD‑L1 dominance. [R34–R36]

**3) Tumor immune microenvironment (TIME) consequences**  
**Spatial phenotype is central:**  
- “Hot” tumors show intratumoral CD3+/CD8+ T cells, “excluded” tumors show stromal trapping, and “desert” tumors lack immune infiltration. [R37–R38]  
- PDAC is profoundly immune‑excluded (≈85% excluded; ≈10% inflamed). NSCLC shows ~24% inflamed, ~51% altered/excluded, ~24% desert; STK11/KEAP1 co‑mutations enrich non‑inflamed states. [R39–R41]  

**Genotype‑to‑TIME mapping (examples):**  
- **MSI‑H CRC**: increased CD8 infiltration (ORs ~2.8–3.5 for multiple CD8 subsets), but PD‑L1‑high MSI‑H CRC shows increased Tregs (~48% increase) and reduced GzmB/IFN‑γ, consistent with inflamed‑but‑exhausted states. [R42–R43]  
- **KRAS‑driven PDAC**: tumor‑cell GM‑CSF and IL‑1β recruit MDSCs/M2 macrophages and drive desmoplasia, promoting immune exclusion; loss of tumor‑cell IL‑1β can permit CD8 infiltration. [R44–R45]  
- **STK11/LKB1 + KEAP1**: suppress STING/Type I IFN, reduce functional CD8 responses, and bias toward cold, T‑cell‑poor TIME. [R46–R47]  
- **CIN/SCNA‑high tumors**: reduced cytotoxic immune signatures across TCGA; chronic cGAS‑STING activation can switch to non‑canonical NF‑κB signaling and immune suppression. [R48–R50]

**4) Clinical translation (2023–2025 highlights)**  
- **MSI‑H/dMMR mCRC**: CheckMate 8HW showed dramatic PFS improvement (median PFS not reached vs 5.8 months; HR 0.21) and ORR 71% vs 58% with dual‑ICI; led to FDA approval on **April 8, 2025** for nivo+ipi in MSI‑H/dMMR CRC. [R51–R52]  
- **TMB‑H tissue‑agnostic**: randomized phase‑2 evidence shows higher ORR with nivo+ipi vs nivo alone in TMB‑H tumors. [R53]  
- **STK11/KEAP1‑mutant NSCLC**: POSEIDON long‑term OS benefit with CTLA‑4 add‑on to PD‑(L)1 + chemo (5‑year OS 15.7% vs 6.8%); biomarker‑stratified analysis supports benefit in STK11/KEAP1 subsets. [R54–R55]  
- **KRAS G12C + PD‑1**: KRYSTAL‑7 shows encouraging ORR (~63% in PD‑L1‑high), but remains early/conference‑driven and requires phase‑3 validation. [R56]  
- **Next‑gen checkpoints**: Tebotelimab (PD‑1×LAG‑3) shows modest monotherapy ORR; TIGIT failed OS in SKYSCRAPER‑01. [R57–R58]  
- **Vaccines and cell therapy**: mRNA‑4157/V940 + pembrolizumab improved RFS in resected high‑risk melanoma; lifileucel (Amtagvi) gained FDA accelerated approval Feb 16, 2024 with ORR 31.5% and durable responses. [R59–R60]  

---

**III. Translational Implications**  
- **MSI‑H ≠ guaranteed response:** High TMB/MSI increases immunogenicity, but frequent APM defects (B2M/HLA/TAP/NLRC5) explain resistance and support combined strategies that bypass MHC‑I loss (e.g., NK‑cell or macrophage‑targeting, bispecifics, or MHC‑II‑directed approaches). [R16–R19]  
- **STK11/KEAP1 cold phenotypes:** Mechanistic silencing of STING/IFN signaling provides a rational basis for adding CTLA‑4 blockade and/or innate‑immune agonists, with clinical support in NSCLC. [R30–R31, R54–R55]  
- **KRAS‑driven myeloid bias:** GM‑CSF and IL‑1β pathways align with MDSC‑rich, excluded TIME, suggesting combinatorial myeloid‑directed immunotherapy in KRAS‑mutant, desmoplastic tumors. [R44–R45]  
- **CIN‑high tumors:** Correlated immune suppression and chronic STING signaling argue for careful patient selection and timing of STING‑pathway modulation rather than universal activation strategies. [R48–R50]  
- **Clinical biomarker prioritization:** MSI‑H is validated for dual‑checkpoint use; TMB‑H has signal but remains threshold‑dependent; STK11/KEAP1 are emerging for CTLA‑4 add‑on; TP53 and CIN remain investigational for treatment selection. [R51–R55]

---

**IV. Key Challenges and Knowledge Gaps**  
- **Thresholds are not portable:** TMB‑high and CIN metrics vary by histology, assay, and cohort, limiting cross‑trial comparability and biomarker cutoffs. [R6–R7, R11–R12]  
- **MSI‑H prevalence depends on assay platform:** tissue vs ctDNA shows substantial differences, complicating eligibility and prevalence estimates. [R8–R10]  
- **Context‑dependent NRF2/PD‑L1 biology:** opposite directions reported across tumor types, suggesting lineage‑specific co‑factors. [R32–R33]  
- **STK11 mutation vs STK11‑deficiency:** functional transcriptional states may better predict TIME than DNA alteration alone. [R46]  
- **CIN‑stratified trials are lacking:** despite strong mechanistic rationale, patient selection by CIN is not yet tested prospectively. [R48–R50]  
- **TP53 as immunotherapy biomarker remains unvalidated:** no definitive randomized TP53‑stratified results published for ICI combinations. [R61]  

---

**V. Future Directions**  
1. **Unified biomarker frameworks:** Standardize TMB, MSI, and CIN definitions across assays; incorporate CNA fraction and transcriptomic STK11‑deficiency signatures into prospective trial stratification.  
2. **Functional APM assessment:** Pair MSI‑H/TMB‑H status with APM integrity (B2M/HLA/TAP/NLRC5) to predict ICI resistance and guide alternative immune‑activation strategies.  
3. **Spatial multi‑omics:** Apply spatial transcriptomics + proteomics to map “hot/excluded/desert” phenotypes longitudinally and identify actionable stromal barriers.  
4. **Innate‑immune precision trials:** Test STING‑pathway modulators in biomarker‑defined cohorts (STK11/KEAP1‑mutant, CIN‑high, or IFN‑low tumors), with careful dosing to avoid chronic immunosuppression.  
5. **Myeloid‑directed combinations in KRAS‑driven tumors:** Evaluate CSF‑1R/IL‑1β/GM‑CSF pathway blockade plus ICI in desmoplastic, MDSC‑dominant tumors.  
6. **Mechanism‑guided cellular therapies:** Expand TIL and engineered cell therapies into tumors with APM loss or low T‑cell infiltration, potentially leveraging NK‑cell platforms.  

---

**VI. References (Consolidated)**  
[R1] TCGA Pan‑Cancer Atlas driver landscape (Cell 2018). `https://gdc.cancer.gov/publications/pancan-driver`  
[R2] PCAWG driver analysis (Nature 2020). `https://www.nature.com/articles/s41586-020-1969-6`  
[R3] Pan‑Cancer Atlas mutation burden/CNA fraction (JCO Prec Oncol 2023). `https://pubmed.ncbi.nlm.nih.gov/37276492/`  
[R4] cBioPortal update (NCI 2024). `https://www.cancer.gov/about-nci/organization/cbiit/news-events/news/2024/cbioportal-updates-offer-joint-analysis-genetic-and-clinical-data`  
[R5] AACR GENIE 2025 update. `https://www.aacr.org/professionals/research/aacr-project-genie/news-updates/year-in-review-2025/`  
[R6] Pan‑cancer TMB‑high prevalence meta‑analysis. `https://pmc.ncbi.nlm.nih.gov/articles/PMC9705554/`  
[R7] Histology‑specific TMB cutoffs (MSK‑IMPACT). `https://www.sciencedirect.com/topics/medicine-and-dentistry/tumor-mutation-burden`  
[R8] MSI‑H prevalence in 174,166 advanced cancers (2024). `https://www.nature.com/articles/s41698-024-00679-7`  
[R9] MSI across 39 tumor types (2023). `https://www.mdpi.com/2072-6694/15/8/2288`  
[R10] ctDNA MSI‑H prevalence (2023). `https://pubmed.ncbi.nlm.nih.gov/37769226/`  
[R11] TCGA aneuploidy study (Cancer Cell 2018). `https://pubmed.ncbi.nlm.nih.gov/29622463/`  
[R12] LUAD meta‑cohort driver frequencies (2024). `https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1357583/full`  
[R13] CRC driver frequencies (TCGA). `https://pmc.ncbi.nlm.nih.gov/articles/PMC8034139/`  
[R14] PDAC driver frequencies (TCGA vs GENIE/MSK). `https://pmc.ncbi.nlm.nih.gov/articles/PMC8382872/`  
[R15] HGSOC TP53 prevalence (TCGA‑anchored). `https://journals.lww.com/intjgynpathology/fulltext/2022/11001/data_set_for_the_reporting_of_ovarian%2C_fallopian.9.aspx`  
[R16] MSI CRC APM lesion frequency (B2M/HLA/TAP/NLRC5). `https://pmc.ncbi.nlm.nih.gov/articles/PMC5993484/`  
[R17] MSI‑H/dMMR B2M mutation rates across tumors. `https://academic.oup.com/oncolo/article/28/3/e136/7022155`  
[R18] HLA‑A2–β2m–peptide structure. `https://www.rcsb.org/structure/1AKJ`  
[R19] Peptide‑loading complex (PLC) structure. `https://www.nature.com/articles/nature24627`  
[R20] Tapasin–MHC‑I editing structure. `https://www.nature.com/articles/s41467-022-33153-8`  
[R21] cGAS–DNA structure. `https://www.rcsb.org/structure/6CT9`  
[R22] STING–cGAMP structure. `https://www.rcsb.org/structure/4KSY`  
[R23] Micronuclei activate cGAS‑STING (Nature 2017). `https://www.nature.com/articles/nature23449`  
[R24] IFN‑γ–JAK‑STAT–IRF1 induction of PD‑L1. `https://pmc.ncbi.nlm.nih.gov/articles/PMC6420824/`  
[R25] KRAS G12 mutation signaling state. `https://pubmed.ncbi.nlm.nih.gov/31611389/`  
[R26] MAPK/ERK→AP‑1 control of PD‑L1 in KRAS‑mutant LUAD. `https://pmc.ncbi.nlm.nih.gov/articles/PMC5112979/`  
[R27] p53 upregulates TAP1. `https://pubmed.ncbi.nlm.nih.gov/10618714/`  
[R28] p53 upregulates ERAP1. `https://pmc.ncbi.nlm.nih.gov/articles/PMC3759077/`  
[R29] p53 loss blunts IFN‑γ–PD‑L1 via JAK2. `https://jeccr.biomedcentral.com/articles/10.1186/s13046-019-1403-9`  
[R30] LKB1 loss silences STING via epigenetic mechanisms. `https://pubmed.ncbi.nlm.nih.gov/30297358/`  
[R31] KEAP1/STK11 redox phenotype suppresses STING/MDA5. `https://pmc.ncbi.nlm.nih.gov/articles/PMC12685646/`  
[R32] KEAP1/NRF2 modulation of PD‑L1 (CRISPR screen). `https://pmc.ncbi.nlm.nih.gov/articles/PMC12630863/`  
[R33] NRF2/PD‑L1 co‑elevation in colon cancer (context dependence). `https://pmc.ncbi.nlm.nih.gov/articles/PMC12630863/`  
[R34] PD‑1/PD‑L1 complex structure. `https://www.rcsb.org/structure/4ZQK`  
[R35] CTLA‑4/CD80 structure. `https://www.ncbi.nlm.nih.gov/Structure/pdb/1I8L`  
[R36] TIGIT/CD155 and LAG‑3/HLA‑DR structures. `https://www.rcsb.org/structure/3UDW` and `https://www.rcsb.org/structure/9BF9`  
[R37] Immune‑inflamed/excluded/desert definitions. `https://elifesciences.org/articles/62927`  
[R38] Chen & Mellman cancer‑immunity cycle framework. `https://www.nature.com/articles/nature21349`  
[R39] PDAC spatial immune phenotyping (excluded‑dominant). `https://pubmed.ncbi.nlm.nih.gov/40560550/`  
[R40] NSCLC spatial CD8 phenotyping with STK11/KEAP1 enrichment in cold tumors. `https://pubmed.ncbi.nlm.nih.gov/37100205/`  
[R41] Pan‑cancer immune landscape (TCGA). `https://pmc.ncbi.nlm.nih.gov/articles/PMC5982584/`  
[R42] MSI‑H CRC CD8 subset ORs. `https://pubmed.ncbi.nlm.nih.gov/39763680/`  
[R43] MSI‑H CRC PD‑L1‑high Treg/IFN‑γ suppression. `https://www.nature.com/articles/s41467-024-51386-7`  
[R44] KRAS G12D induces GM‑CSF and MDSCs in pancreatic neoplasia. `https://pubmed.ncbi.nlm.nih.gov/22698407/`  
[R45] PDAC tumor‑cell IL‑1β drives desmoplasia; loss permits CD8 infiltration. `https://pubmed.ncbi.nlm.nih.gov/31915130/`  
[R46] STK11‑deficient phenotypes and STING/IFN disruption. `https://pubmed.ncbi.nlm.nih.gov/37495171/`  
[R47] KEAP1/NRF2 suppresses STING pathway in KRAS/KEAP1 co‑mutant NSCLC. `https://pubmed.ncbi.nlm.nih.gov/37492744/`  
[R48] SCNA/CIN correlates with reduced cytotoxic immune signatures. `https://pmc.ncbi.nlm.nih.gov/articles/PMC5592794/`  
[R49] CIN‑driven cGAS‑STING can promote metastasis via noncanonical NF‑κB. `https://pubmed.ncbi.nlm.nih.gov/29342134/`  
[R50] Review on dual cGAS‑STING effects in CIN. `https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-025-06843-2`  
[R51] CheckMate 8HW results. `https://pubmed.ncbi.nlm.nih.gov/39107131/`  
[R52] FDA approval of nivo+ipi in MSI‑H/dMMR CRC (Apr 8, 2025). `https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-ipilimumab-unresectable-or-metastatic-msi-h-or-dmmr-colorectal-cancer`  
[R53] TMB‑H nivo+ipi vs nivo (NCT03668119). `https://pubmed.ncbi.nlm.nih.gov/39107131/`  
[R54] POSEIDON 5‑year OS benefit in NSCLC. `https://pubmed.ncbi.nlm.nih.gov/39243945/`  
[R55] Biomarker‑stratified CTLA‑4 benefit in STK11/KEAP1 (Nature 2024). `https://www.nature.com/articles/s41586-024-07943-7`  
[R56] KRYSTAL‑7 interim results (PD‑L1‑high ORR ~63%). `https://pmc.ncbi.nlm.nih.gov/articles/PMC11153770/`  
[R57] Tebotelimab PD‑1×LAG‑3 (Nat Med 2023). `https://pmc.ncbi.nlm.nih.gov/articles/PMC10667103/`  
[R58] SKYSCRAPER‑01 TIGIT OS failure (Roche 2024). `https://www.roche.com/media/releases/med-cor-2024-11-26`  
[R59] KEYNOTE‑942 mRNA‑4157/V940 + pembrolizumab (Lancet 2024). `https://pubmed.ncbi.nlm.nih.gov/38246194/`  
[R60] Lifileucel FDA approval (Feb 16, 2024). `https://www.fda.gov/news-events/press-announcements/fda-approves-first-cellular-therapy-treat-patients-unresectable-or-metastatic-melanoma`  
[R61] TP53 immunotherapy stratification gap (summary). `https://pubmed.ncbi.nlm.nih.gov/39243945/`

================================================================================
EXECUTION SUMMARY
================================================================================
Domain experts:         4
Total research output:  40,736 chars
Synthesis output:       16,956 chars
Total elapsed time:     561.4s
Status:                 All agents completed successfully!